Abstract
A series of benzo[d]isothiazole-1,1-dioxides were designed and evaluated as inhibitors of HCV polymerase NS5B. Structure-based design led to the incorporation of a high affinity methyl sulfonamide group. Structure-activity relationship (SAR) studies of this series revealed analogues with submicromolar potencies in the HCV replicon assay and moderate pharmacokinetic properties. SAR studies combined with structure based drug design focused on the sulfonamide region led to a novel and potent cyclic analogue.
MeSH terms
-
Animals
-
Antiviral Agents / chemical synthesis*
-
Antiviral Agents / chemistry
-
Antiviral Agents / pharmacokinetics
-
Binding Sites
-
Crystallography, X-Ray
-
Haplorhini
-
Hepacivirus / drug effects*
-
Rats
-
Structure-Activity Relationship
-
Thiazoles / chemical synthesis
-
Thiazoles / chemistry*
-
Thiazoles / pharmacokinetics
-
Viral Nonstructural Proteins / antagonists & inhibitors*
-
Viral Nonstructural Proteins / metabolism
Substances
-
Antiviral Agents
-
Thiazoles
-
Viral Nonstructural Proteins
-
NS-5 protein, hepatitis C virus